Rich Fitzgerald

Biography

    Mr. Fitzgerald has 32 years of progressive financial and commercial experience supporting large established companies as well as development stage enterprises.  From October 2015 through March 2017, Mr. Fitzgerald served as the Chief Financial Officer and Secretary of PAVmed Inc. (NASDAQ: PAVM), a highly differentiated, multi-product medical device company, where he led the initial build out of the company’s finance and administrative infrastructure, supported the consummation of the company’s initial public offering and established SEC reporting procedures and internal controls for a new public company. Prior to his role at PAVmed, Mr. Fitzgerald served as the Chief Financial Officer of TechPrecision (OTCQB:TPCS) from March 2009 through October 2015.  TechPrecision is an industry leading global manufacturer of precision, large-scale fabricated and machined metal components and tested systems with customers in the naval/maritime, energy, nuclear power, medical device and precision industrial sectors.  From 2002 until December 2008, Mr. Fitzgerald served in a variety of senior financial roles at Nucleonics, Inc., a private venture capital backed, biotechnology company, eventually becoming Vice-President and Chief Financial Officer of Nucleonics, Inc. in February 2008. While at Nucleonics, Mr. Fitzgerald led efforts that enabled Nucleonics to secure over $65 million in venture capital as an early pioneer within the field of RNAi therapeutics.  Nucleonics’ intellectual property and drug development programs were sold to Alnylam Pharmaceuticals, Inc., (ALNY:NASDAQ), in December 2008.  While at Nucleonics, Mr. Fitzgerald was appointed to serve as the co-Chair of BIO’s CFO/Tax VP Committee and was active in the Association of Biotechnology Financial Officers both locally and nationally in the U.S.

Research Interest

 Business